Study design (if review, criteria of inclusion for studies)
Multicenter retrospective study
Participants
13 adults and adolescents with CFRD
Interventions
Tandem t:slim X2 pump with Control IQ⢠technology, a HCL system.
Outcome measures
14 days of continuous glucose monitor data were analyzed at baseline, 1 and 3 months after transition to the Tandem t:slim X2 pump with Control IQ⢠technology
Main results
Control IQ initiation was associated with a significant increase in % time in target range (70-180âmg/dL), as well as decreases in average glucose, % time in hyperglycemic ranges (% time >180âmg/dL, % time >250âmg/dL), and glycemic variability (standard deviation, coefficient of variation). There was no significant change in % time in hypoglycemia ranges (% time <54âmg/dL, % time <70âmg/dL).
Authors' conclusions
This is the first study to report a beneficial effect of Food and Drug Administration (FDA)-approved HCL technology on glycemia in adults and adolescents with CFRD to date. Future studies are needed to understand the potential long-term glycemic benefits of HCL devices and to explore the impact of this technology on heath-related quality of life, pulmonary function, nutritional status, and mortality.